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Background: Even if carried out under optimal conditions, postdural puncture headache is still 
a frustrating and unpleasant complication in spinal anesthesia. This syndrome has an estimated 
incidence from less than 1% to about 5% of patients undergoing spinal anesthesia, even in the 
highest risk subset, the young, female, and pregnant population.
Case presentation: In our two female cases, headaches started following spinal anesthesia 
on the 11th and 14th hours, respectively. No response was obtained from patients diagnosed 
with postdural puncture headache with classical treatments such as bed rest, hydration, oral 
analgesic, and caffeine combination as well as intravenous theophylline application. The treat-
ment of oral pregablin, commonly used for cases that rejected epidural blood patch, caused a 
significant decrease in headache severity. Later, the two cases whose headaches were completely 
resolved were discharged from the hospital on the post-operative 7th day.
Conclusion: Postdural puncture headache is one of the most common complications of spinal 
anesthesia. Cerebral spinal fluid leakage into the epidural space has been proposed as the main 
mechanism responsible for this syndrome. Multiple methods of treatment have been applied 
with wide-ranging results. We detected that oral pregabalin application caused a significant 
decrease in the difficult and severe postdural puncture headaches of both our cases who did not 
respond to conventional treatments.
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Introduction
The first spinal anesthesia was carried out by Dr August Bier in 1899 and his anes-
thetic technique has become the standard practice for lower extremity and abdominal 
surgery worldwide. However, interestingly enough, the syndrome of postdural puncture 
headache (PDPH) was first described by Dr Bier in 1899.1
PDPH is still the most common postoperative complication of spinal anesthesia. 
The following factors are thought to influence the incidence of PDPH: age, sex, needle 
size, multiple dural punctures, and previous history of PDPH.2 Despite the fact that 
various mechanisms have been proposed for the cause of PDPH, the real etiology is 
not fully understood.
PDPH typically begins within two days (following spinal anesthesia procedure) but 
may be delayed for as long as two weeks and resolves spontaneously within a few days. 
Overhydration, peroral caffeine and theophylline, corticotropin, sumatriptan, epidural 
saline injection, and epidural blood patch (EBP) are the most common treatments.3,4
We have had positive results with oral pregabalin application in our two cases 
with resistant PDPHs that had not responded to the applied conventional classical 
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Case presentation
Case 1, a 38-year-old woman, weighing 83 kg and 162 cm 
tall (body mass index [BMI]: 31.6 kg/m2), was scheduled for 
vaginal hysterectomy operation. She had not been operated 
on previously. Case 2, a 21-year-old woman, weighing 62 kg 
and 151 cm tall (BMI: 27.2 kg/m2), was scheduled for an 
inguinal hernia operation. The case had an appendectomy 
nine years ago under general anesthesia. Written informed 
consent was obtained from the patients for the publication 
of this case report and accompanying images.
The two cases did not have any systemic diseases and 
their pre-operative neurologic examination findings as well as 
biochemical and hematologic laboratory values were normal. 
Both patients were hydrated with at least 0.5 L of intravenous 
(iv) crystalloid solution before the procedure. Standard moni-
toring was used including noninvasive arterial blood pressure 
(NIBP), heart rate (HR), and pulse oximetry (SPO2). Dural 
puncture was performed at the L3–4 interspace, in the sitting 
position, using a midline approach with 25-gauge Quincke 
spinal needles (Becton Dickinson, Franklin Lakes, NJ, 
USA). The bevel of the needle was kept parallel to the dural 
fibers. After observing the flow of cerebrospinal fluid (CSF) 
through the needle, 3 mL of 0.5% hyperbaric bupivacaine 
was injected. In both of two patients, spinal anesthesia was 
induced with a single puncture.
Surgical procedures were successfully carried out along 
with spinal anesthesia on our two cases whose spinal block 
levels had increased to Th 10-11 dermatome level. Headaches 
of the cases, whose motor and sensory blocks were com-
pletely over, started respectively on the 11th and 14th hours 
following the spinal anesthesia procedure. According to the 
anamnesis (severe visual analog scale [VAS]: 8–9 cm, dull 
permanent and nonthrobbing pain in fronto-occipital loca-
tion) and examination findings (moderate to severe headache 
when sitting or ambulating and no neck stiffness) of the two 
cases, it was decided that they had PDPH.
Both cases were started a combined oral medication 
containing paracetamol and caffeine (300 mg/day) with bed 
rest and hydration (not agresssive). Twenty-four hours after 
the beginning of treatment, there was no alleviation of the 
pains and as nausea also started, theophylline application was 
started. Two cases were given 200 mg intravenous theophyl-
line (200 mg theophylline in 100 mL 5% dextrose) infusion 
over 40 minutes so cases who didn’t report any decrease of 
VAS pretreatment values, four hours after the theophylline 
infusion were given a second theophylline infusion under the 
same conditions. Headaches did not respond to this treatment, 
although neurologic examination of the cases was normal and 
meningeal irritation findings were negative; therefore cranial 
tomographies of both cases were taken but no pathological 
conditions were detected.
Thirty-six hours after the beginning of the headaches, 
EBP was offered to the patients. However, both patients 
mentioned that they had been having headaches due to spinal 
anesthesia and that they would not accept another injection 
on the same area even for treatment. Therefore, we did not 
have a chance to use EBP for our cases.
Thereupon, we decided to use pregabalin containing an 
analogue gamma-aminobutyric acid such as gabapentin5,6 
that has been shown to have positive effects on PDPH. Oral 
pregabalin treatment of 150 mg/day (50 mg at eight-hour 
intervals) was started. Following the first dose, on the 2nd 
and 3rd hours, respectively, there was a decrease in the 
headache VAS scores of the cases. After the 12th hour, VAS 
values were below 3. During the subsequent three-day pre-
gabalin treatment, the cases did not complain of headache. 
Thereupon, one daily medication dose was skipped and it 
was stopped after two days. The patients did not complain 
of headache. No side effects except sedation were observed 
during treatment and, we believe, the cases who had been 
suffering from headaches for two days were in need of seda-
tion. Both cases were discharged from the hospital on the 
post-operative 7th day without any problem. The patients 
were called for an examination after one month and no 
pathological findings were observed.
Discussion
More than 100 years have passed since the initial description 
of the PDPH and it still continues to occur.1 The International 
Classification of Headache Disorders, 2nd edition describes 
PDPH under paragraph 7.2.1.7
PDPH is postulated to be a consequence of one of two non-
mutually exclusive mechanisms, both involving CSF leaking 
through a needle-induced dural hole. One hypothesis is that 
this decrease in CSF results in an increase blood volume from 
vasodilation secondary to the Monro–Kellie doctrine because 
the sum of the volumes of the brain matter, CSF, and blood must 
remain the same. The second hypothesis is that the decrease in 
CSF volume results in sagging of the brain in the cranial vault 
when the patient assumes the upright position, which pulls on 
the falx cerebri, cerebral blood vessels, and tentorium, result-
ing in excruciating positional head pain. This headache may 
be accompanied by occiput, neck and shoulder pain, upper 
limb pains or paresthesias, nausea and vomiting, photophobia 
or cranial nerve palsies including but not limited to diplopia, 
visual blurring, and hearing loss. cerebrospinal fluid.8Journal of Pain Research 2010:3
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Risk factors for PDPH include young age, lesser body 
mass index, female gender, pregnancy and labor, history of 
recurrent headaches or previous PDPH, size of the needle, 
direction of the cutting needle bevel when puncturing the 
dura, and other technical factors in the performance of lumbar 
puncture.9,10 Although relatively thin spinal needles (25-gauge 
Quincke spinal needle) were used, the procedure was com-
pleted at once and needle direction was parallel to the dura, 
we came across with PDPH in our cases and we believe this 
was due to the fact that in both cases were relatively young 
(aged below 40 years) and female.
The classic PDPH is described as a severe, dull, nonthrob-
bing pain usually fronto-occipital in location. It is now recog-
nized that the patient may also suffer from associated nausea, 
vomiting, visual disturbances, tinnitus or deafness.2 PDPH 
can be severe and is usually aggravated by sitting, standing, 
and walking because of the descending shift of the brain, 
which stretches pain-sensitive meningeal structures.11,12
Therapy for PDPH begins with proper diagnosis. Mis-
diagnosis is a strong possibility. In particular, the physician 
should be careful to rule out treatable catastrophic medical 
problems such as meningitis and subarachnoid bleeding. 
Once the diagnosis is made, most authors recommend 
24 hours of conservative therapy, since the natural history 
is one of spontaneous resolution.2 Bed rest is effective in 
that it avoids the upright position, which aggravates PDPH. 
Analgesics given orally, including mild opiates, also routinely 
bring some relief during the observational period. Aggres-
sive hydration and tight abdominal binders are no longer 
recommended.
If the headache persists and is disabling to the patient, 
or if nausea, vomiting, visual disturbance or tinnitus occurs, 
the diagnosis should be reconsidered. Once other important 
causes of severe headache are again ruled out, the therapeutic 
options include caffeine given intravenously, an EBP and 
epidural administration of saline.2
Pharmacological management of PDPH is a minimally 
invasive treatment modality. Severe headaches such as 
PDPH commonly present with nausea and this limits the 
effect of peroral medications. It would be useful to use 
parenteral medications for rapid and effective treatment 
and a noninvasive procedure is preferable. However, 
invasive treatments (like EBP etc.) for PDPH have known 
complications, such as infection and exacerbation of pain.13 
When EBP is used in patients suffering from moderate to 
severe or prolonged PDPH, two mechanisms likely bring 
about this effect: formation of a plug in the dural defect, 
which stops the loss of CSF, and simultaneous reduction in 
the volume of the subarachnoid space through expansion 
of the epidural space, which eliminates the relative CSF 
deficiency.14
Pregabalin, like gabapentin, is an antiepileptic drug 
and a structural analogue of gamma-aminobutyric acid 
(GABA). Pregabalin does not undergo hepatic metabolism 
and is not bound to plasma proteins. It is renally excreted, 
and 98% of the absorbed dose is excreted unchanged in the 
urine. Absorption of pregabalin is not saturable (contrary to 
gabapentin), resulting in a linear pharmacokinetic profile. 
It is rapidly absorbed with peak blood concentrations within 
one hour. Average bioavailability exceeds 90% (higher 
than gabapentin) and is independent of dose, which may 
produce a more predictable patient response. The elimination 
half-life of pregabalin ranges from 5.5 to 6.7 hours, and is 
independent of dose (contrary to gabapentin) and repeated 
dose administration.15 Pregabalin binds to the alpha-2-delta 
subunit of the N-type calcium channels, and modulates 
calcium influx at nerve terminals, and, thereby, reduces the 
release of several neurotransmitters, including glutamate, 
noradrenaline, serotonin, dopamine, and substance P.16
Cabrera Schulmeyer and colleagues17 determined 
that a single dose of pregabalin reduced postoperative 
  morphine consumption after a sleeve gastrectomy during 
the first 24 hours after surgery. Freedman and colleauges18 
found out that perioperative pregabalin administration in 
patients undergoing augmentation mammaplasty reduced 
  postoperative narcotic use by 70%. Agarwal and colleagues’ 
study results showed that a single preoperative oral dose of 
pregabalin is an effective method for reducing postopera-
tive pain and fentanyl consumption in patients undergoing 
laparoscopic cholecystectomy.19
On the other hand, pregabalin, like gabapentin, was 
shown to be effective in several animal models of neuropathic 
pain, incisional injury, inflammatory injury, and formalin-
induced injury.15 However, studies have demonstrated that 
a clinically efficacious dose of chronic oral pregabalin 
inhibits measures of central sensitization in the electrical 
hyperalgesia model in human volunteers.20 Thus pregabalin, 
which has been effective in reducing hyperalgesia in pain 
model, may play an important role in acute postoperative 
pain in humans.
Eventually, maybe the exact mechanism of action of 
pregabalin is not well understood but clinical experience and 
our observations have demonstrated its analgesic efficacy 
and safety in PDPH. Our findings (via two patients) dem-
onstrated that 150 mg/day of oral pregabalin significantly 
decreases PDPH.Journal of Pain Research 2010:3
Journal of Pain Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-pain-research-journal
The Journal of Pain Research is an international, peer-reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
14
Zencirci
Conclusion
PDPH continues to be a major problem for spinal anesthesia. 
Different treatment modalities have been implemented on 
patients with PPDH, including bed rest, hydration or over-
hydration, peroral caffeine or theophylline, corticosteroids, 
sumatriptan, abdominal binder, EBP, epidural saline infusion, 
etc. In the light of the positive results we received from the 
two cases, we believe oral pregabalin application could be 
an alternative for stubborn PDPH cases that do not respond 
to classical treatments and that further studies are required 
on this subject.
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